Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Maravai Lifesciences Holdings (MRVI) Non-Current Assets: 2020-2024

Historic Non-Current Assets for Maravai Lifesciences Holdings (MRVI) over the last 5 years, with Dec 2024 value amounting to $579.1 million.

  • Maravai Lifesciences Holdings' Non-Current Assets fell 12.65% to $523.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $523.3 million, marking a year-over-year decrease of 12.65%. This contributed to the annual value of $579.1 million for FY2024, which is 26.47% down from last year.
  • According to the latest figures from FY2024, Maravai Lifesciences Holdings' Non-Current Assets is $579.1 million, which was down 26.47% from $787.5 million recorded in FY2023.
  • In the past 5 years, Maravai Lifesciences Holdings' Non-Current Assets registered a high of $1.4 billion during FY2022, and its lowest value of $579.1 million during FY2024.
  • Its 3-year average for Non-Current Assets is $933.7 million, with a median of $787.5 million in 2023.
  • Per our database at Business Quant, Maravai Lifesciences Holdings' Non-Current Assets rose by 25.47% in 2021 and then tumbled by 45.10% in 2023.
  • Over the past 5 years, Maravai Lifesciences Holdings' Non-Current Assets (Yearly) stood at $939.1 million in 2020, then climbed by 25.47% to $1.2 billion in 2021, then rose by 21.74% to $1.4 billion in 2022, then slumped by 45.10% to $787.5 million in 2023, then fell by 26.47% to $579.1 million in 2024.